No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ERAS Erasca
- 1.930
- +0.080+4.32%
Close Apr 23 16:00 ET
- 2.060
- +0.130+6.74%
Post 19:19 ET
292.38MMarket Cap-2325P/E (TTM)
1.974High1.850Low443.62KVolume1.850Open1.850Pre Close859.22KTurnover0.52%Turnover RatioLossP/E (Static)151.49MShares3.37552wk High0.92P/B166.16MFloat Cap1.51052wk Low--Dividend TTM86.09MShs Float24.470Historical High--Div YieldTTM6.68%Amplitude1.510Historical Low1.936Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersChromocell Therapeutics (AMEX:CHRO) stock increased by 21.6% to $1.49 during Friday's pre-market session. The company's market cap stands at $8.7 million. Kineta (NASDAQ:KA) stock moved upwards
Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating
Erasca Is Maintained at Buy by Goldman Sachs
Erasca Is Maintained at Buy by Goldman Sachs
Express News | Goldman Sachs Maintains Buy on Erasca, Raises Price Target to $7
Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript
Analysts Are Bullish on These Healthcare Stocks: Erasca (ERAS), Disc Medicine (IRON)
Comments
Erasca's private placement financing is viewed positively, extending its cash runway into H2 2026 and enabling continued R&D efforts. The company's focus on RAS/MAPK pathway-driven cancers and its promising pipeline have drawn investor interest.
Press Release: Erasca Announces $45 Million Oversubscribed Private Placement Financing 1
The insider purchases, especially at higher prices, suggest bullishness about the company. The level of insider ownership indicates a decent alignment of interests with other shareholders. Despite the company incurring losses, insiders seem optimistic about the stock potentially being undervalued.
ColumnsToday's pre-market stock movers: RKLB, ILMN, TOST, BABA and more
Gainers:
In reaction to earnings/guidance:
• $Payoneer Global(PAYO.US$ +19.4%,$Toast(TOST.US$ +13.1%,$PDF Solutions(PDFS.US$ +7.7%,$Wheels Up Experience(UP.US$ +7.1%,$LegalZoom(LZ.US$ +6.5%,$Joby Aviation(JOBY.US$ +3.6%,$indie Semiconductor(INDI.US$ +2.9%,$Rocket Lab(RKLB.US$ +2.4%,$Rivian Automotive(RIVN.US$ +1.2%
Other news:
• $WeTrade Group(WETG.US$ +47.8%(announces $50 million sales of monkeypox virus test kits to Par...
In reaction to earnings/guidance:
• $Payoneer Global(PAYO.US$ +19.4%,$Toast(TOST.US$ +13.1%,$PDF Solutions(PDFS.US$ +7.7%,$Wheels Up Experience(UP.US$ +7.1%,$LegalZoom(LZ.US$ +6.5%,$Joby Aviation(JOBY.US$ +3.6%,$indie Semiconductor(INDI.US$ +2.9%,$Rocket Lab(RKLB.US$ +2.4%,$Rivian Automotive(RIVN.US$ +1.2%
Other news:
• $WeTrade Group(WETG.US$ +47.8%(announces $50 million sales of monkeypox virus test kits to Par...
16
2
ColumnsIPO Buzz: Shopping center REIT PECO leads a 15-deal week
$Unicycive Therapeutics(UNCY.US$$F45 Training(FXLV.US$$Membership Collective Group Inc.(MCG.US$$Phillips Edison(PECO.US$$Rapid Micro Biosystems(RPID.US$$Sera Prognostics(SERA.US$$Sight Sciences(SGHT.US$$Blend Labs(BLND.US$$Bridge Investment(BRDG.US$$Dynacure(DYCU.US$$Erasca(ERAS.US$$Imago BioSciences, Inc.(IMGO.US$$Perspectum Group(SCAN.US$
Expand 46
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg